240 related articles for article (PubMed ID: 31012089)
1. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
Wong GN; Lee S; Foley P
Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
[No Abstract] [Full Text] [Related]
2. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
3. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
5. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
Alten R; Nitschmann S
Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
[No Abstract] [Full Text] [Related]
6. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment.
Wilson LM; Reid CM
Australas J Dermatol; 2004 Aug; 45(3):184-5. PubMed ID: 15250900
[TBL] [Abstract][Full Text] [Related]
7. Journal club: New small molecules for atopic dermatitis management.
Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E
Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077
[No Abstract] [Full Text] [Related]
8. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
Xia D; Xiao Y; Li M; Li W
Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
[No Abstract] [Full Text] [Related]
9. Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus.
Lerbaek A; Agner T
Br J Dermatol; 2004 Jun; 150(6):1210-1. PubMed ID: 15214914
[No Abstract] [Full Text] [Related]
10. Dupilumab may facilitate the clearance of molluscum contagiosum in atopic dermatitis patients.
Di Lernia V; Casanova DM; Simonetti V
J Dtsch Dermatol Ges; 2020 Sep; 18(9):1016-1018. PubMed ID: 32881369
[No Abstract] [Full Text] [Related]
11. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
Vanderver A; Adang L; Gavazzi F; McDonald K; Helman G; Frank DB; Jaffe N; Yum SW; Collins A; Keller SR; Lebon P; Meritet JF; Rhee J; Takanohashi A; Armangue T; Ulrick N; Sherbini O; Koh J; Peer K; Besnier C; Scher C; Boyle K; Dubbs H; Kramer-Golinkoff J; Pizzino A; Woidill S; Shults J
N Engl J Med; 2020 Sep; 383(10):986-989. PubMed ID: 32877590
[No Abstract] [Full Text] [Related]
12. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
14. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
Wollenberg A; Lio P; Kleyn E; Bissonnette R; Jose Rueda M; Casillas M; Chen YF; Lu N; Schloebe A; Simpson E
Eur J Dermatol; 2022 Jul; 32(4):522-529. PubMed ID: 36301752
[TBL] [Abstract][Full Text] [Related]
15. Eczema molluscatum in tacrolimus treated atopic dermatitis.
Wetzel S; Wollenberg A
Eur J Dermatol; 2004; 14(1):73-4. PubMed ID: 14965804
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
17. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
18. Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F; Malvaso D; Caldarola G; Simone C; Peris K; Chiricozzi A
Immunotherapy; 2023 Dec; 15(18):1521-1529. PubMed ID: 37850366
[TBL] [Abstract][Full Text] [Related]
19. Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis.
Raimondo A; Guglielmi G; Marino C; Ligrone L; Lembo S
Clin Exp Dermatol; 2022 Mar; 47(3):592-593. PubMed ID: 34655234
[No Abstract] [Full Text] [Related]
20. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
